Literature DB >> 3025332

Autoantibodies to neurofibrillary tangles and brain tissue in Alzheimer's disease. Establishment of Epstein-Barr virus-transformed antibody-producing cell lines.

F Gaskin, B S Kingsley, S M Fu.   

Abstract

Multiple EBV-transformed B cell lines were established from five patients with a clinical diagnosis of Alzheimer's disease (AD) and six age-matched controls. The supernatants were screened for antibody activity against SDS-treated isolated neurofibrillary tangles (NFT). Reactive supernatants were identified from both the AD and control group. The frequencies of anti-NFT antibody-secreting lines were 6.3 and 1.6% for the AD and the control groups, respectively. A proportion of these supernatants also stained NFT in situ and neurons and/or glia in sections of the frontal and the temporal cortexes of autopsied AD and normal brains, as well as cells from three cell lines (HeLa, fibroblast, and neuroblastoma). Several patterns of staining were revealed by these supernatants, indicating different reactive antigens. One supernatant stained NFT and astrocytes in sections from AD brains. It did not stain sections from two normal brains. This cell line is the result of the immortalization of a circulating B cell making antibody specific for an antigen in AD. The present approach may provide new insights in the pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3025332      PMCID: PMC2188248          DOI: 10.1084/jem.165.1.245

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  9 in total

1.  A neuronal antigen in the brains of Alzheimer patients.

Authors:  B L Wolozin; A Pruchnicki; D W Dickson; P Davies
Journal:  Science       Date:  1986-05-02       Impact factor: 47.728

Review 2.  Alzheimer's disease.

Authors:  R Katzman
Journal:  N Engl J Med       Date:  1986-04-10       Impact factor: 91.245

Review 3.  Cytoskeletal protein abnormalities in neurodegenerative diseases.

Authors:  J E Goldman; S H Yen
Journal:  Ann Neurol       Date:  1986-03       Impact factor: 10.422

4.  Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE.

Authors:  T Endo; D D Scott; S S Stewart; S K Kundu; D M Marcus
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

5.  Alzheimer paired helical filaments: bulk isolation, solubility, and protein composition.

Authors:  K Iqbal; T Zaidi; C H Thompson; P A Merz; H M Wisniewski
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

6.  Neurofibrillary tangles in senile dementia of the Alzheimer type share an antigenic determinant with intermediate filaments of the vimentin class.

Authors:  S H Yen; F Gaskin; S M Fu
Journal:  Am J Pathol       Date:  1983-12       Impact factor: 4.307

7.  Fibrous Astrocytes in senile dementia of the Alzheimer type.

Authors:  R Schechter; S H Yen; R D Terry
Journal:  J Neuropathol Exp Neurol       Date:  1981-03       Impact factor: 3.685

8.  Detection of brain autoantibodies in the serum of patients with Alzheimer's disease but not Down's syndrome.

Authors:  V K Singh; H H Fudenberg
Journal:  Immunol Lett       Date:  1986-06       Impact factor: 3.685

9.  Induction of in vitro differentiation and immunoglobulin synthesis of human leukemic B lymphocytes.

Authors:  S M Fu; N Chiorazzi; H G Kunkel; J P Halper; S R Harris
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

  9 in total
  8 in total

1.  Rheumatoid factors isolated from patients with autoimmune disorders are derived from germline genes distinct from those encoding the Wa, Po, and Bla cross-reactive idiotypes.

Authors:  K D Victor; I Randen; K Thompson; O Forre; J B Natvig; S M Fu; J D Capra
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

2.  Complement activation by beta-amyloid in Alzheimer disease.

Authors:  J Rogers; N R Cooper; S Webster; J Schultz; P L McGeer; S D Styren; W H Civin; L Brachova; B Bradt; P Ward
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

Review 3.  Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.

Authors:  Richard Dodel; Frauke Neff; Carmen Noelker; Refik Pul; Yansheng Du; Michael Bacher; Wolfgang Oertel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

4.  Studies of neuroimmune markers in Alzheimer's disease.

Authors:  V K Singh
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

5.  Alzheimer's disease cerebrospinal fluid antibodies display selectivity for microglia. Investigations with cell cultures and human cortical biopsies.

Authors:  A Dahlström; A McRae; R Polinsky; L Nee; B Sadasivan; E A Ling
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

6.  Human antibodies reactive with beta-amyloid protein in Alzheimer's disease.

Authors:  F Gaskin; J Finley; Q Fang; S Xu; S M Fu
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

7.  Human rheumatoid factors with restrictive specificity for rabbit immunoglobulin G: auto- and multi-reactivity, diverse VH gene segment usage and preferential usage of V lambda IIIb.

Authors:  Q Fang; C C Kannapell; F Gaskin; A Solomon; W J Koopman; S M Fu
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

Review 8.  Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach.

Authors:  Hugo Vanderstichele; Thomas Kodadek
Journal:  Alzheimers Res Ther       Date:  2014-04-30       Impact factor: 6.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.